Baminercept News
Most Popular Baminercept Story
Biogen Idec drops baminercept for RA
Biogen Idec said it won't continue developing baminercept for rheumatoid arthritis after the drug failed to hit the primary or secondary endpoints in a Phase II trial. The primary endpoint was Read more...
Latest Headlines
- October 9, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
